Skip to main content

Table 2 Summarized HRs of overall and subgroup analyses for OS

From: Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients

Stratified analysis Study(N) HR z P Heterogeneity
I2 P Estimated method
 OS 95 1.122(1.089–1.156) 7.56 < 0.001 78.20% < 0.001 Random-effect
Subgroup analysis
Publication year
 Early year(~ 2007) 44 1.307(1.212–1.408) 7.01 < 0.001 72.50% < 0.001 Random-effect
 Later year(2007~ 2016) 51 1.101(1.063–1.142) 5.28 < 0.001 81.20% < 0.001 Random-effect
Region
 Europe 30 1.021(1.001–1.042) 2.05 0.041 71.30% < 0.001 Random-effect
 America 13 1.671(1.266–2.205) 3.63 < 0.001 66.60% < 0.001 Random-effect
 Asia 52 1.821(1.623–2.043) 10.21 < 0.001 78.20% < 0.001 Random-effect
Histological type
 SCLC 4 1.023(1.004–1.042) 3.28 0.001 22.30% 0.277 Fixed-effect
 NSCLC 89 1.113(1.081–1.147) 7.11 < 0.001 78.70% < 0.001 Random-effect
 ADC 22 1.219(1.113–1.336) 4.26 < 0.001 76.20% < 0.001 Random-effect
 SQC 9 1.115(0.806–1.542) 0.66 0.512 74.40% < 0.001 Random-effect
Sample size
  < 100 45 1.486(1.340–1.649) 7.71 < 0.001 73.10% < 0.001 Random-effect
  > 100 50 1.083(1.049–1.119) 4.90 < 0.001 81.50% < 0.001 Random-effect
Cutoff value
 L(< 20%) 34 1.962(1.622–2.373) 6.95 < 0.001 74.50% < 0.001 Random-effect
 H(≥20%) 52 1.144(1.094–1.197) 5.91 < 0.001 78.90% < 0.001 Random-effect
Estimated method
 Original data 4 2.043(0.868–4.808) 1.64 0.102 83.90% < 0.001 Random-effect
 Survival curve 23 1.629(1.368–1.940) 5.47 < 0.001 76.30% < 0.001 Random-effect
 HR(univariate) 16 1.511(1.236–1.847) 4.02 < 0.001 56.10% 0.004 Random-effect
 HR(multivariate) 53 1.108(1.063–1.155) 4.87 < 0.001 75.30% < 0.001 Random-effect